Table 2.
Baseline characteristics of patients with ASCVD and concomitant T2DM receiving GLP-1 RA versus those not receiving GLP-1 RA
| GLP-1 RA users | GLP-1 RA nonusers | ||
|---|---|---|---|
| n = 43,118 (8.0%) | n = 494,862 (92.0%) | P value | |
| Age, mean (SD), years | 69.6 (8.0) | 72.8 (9.0) | <0.01 |
| Male sex, n (%) | 41,681 (96.7) | 483,542 (97.7) | <0.01 |
| Race, n (%) | <0.01 | ||
| Non-Hispanic White | 31,902 (74.0) | 349,104 (70.6) | |
| Non-Hispanic Black | 5,374 (12.5) | 77,450 (15.6) | |
| Others | 5,842 (13.5) | 68,608 (13.8) | |
| Hypertension, n (%) | 40,526 (94.0) | 447,646 (90.5) | <0.01 |
| BMI, mean (SD), kg/m2 | 33.9 (6.5) | 31.0 (6.2) | <0.01 |
| HbA1c, mean (SD), % | 8.0 (1.5) | 7.2 (1.4) | <0.01 |
| IHD, n (%) | 35,960 (83.4) | 391,849 (79.2) | <0.01 |
| PAD, n (%) | 10,219 (23.7) | 119,813 (24.2) | 0.11 |
| ICVD, n (%) | 11,018 (25.6) | 134,361 (27.2) | <0.01 |
| Aspirin, n (%) | 32,878 (91.9) | 358,666 (91.6) | 0.06 |
| Any statin, n (%) | 39,950 (92.7) | 427,684 (86.4) | <0.01 |
| High-intensity statin, n (%) | 28,247 (65.5) | 257,891 (52.1) | <0.01 |
| ACE inhibitor or ARB therapy, n (%) | 30,142 (69.9) | 283,917 (57.4) | <0.01 |
| Physician PCP, n (%) | 32,461 (75.3) | 373,819 (75.5) | 0.24 |
| eGFR, mean (SD), mL/min/1.73 m2 | 62.0 (22.5) | 63.8 (22.5) | <0.01 |
| Receipt of care at a teaching facility, n (%) | 14,950 (34.7) | 168,309 (34.0) | <0.01 |
| Visits in the 12 months prior to index PCP visit | |||
| PCP visits, mean (SD), n | 11.0 (7.6) | 7.4 (6.1) | <0.01 |
| Endocrinology visits, mean (SD), n | 0.63 (1.60) | 0.16 (0.82) | <0.01 |
| Cardiology visits, mean (SD), n | 1.00 (2.26) | 0.69 (1.79) | <0.01 |